Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.47 |
| ▸ | CCR1 | P32246 | 5/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL683305 | 0.91 | GFER (0.50) | GFERRAB9AALKCCR1CTSB | |
| SCHEMBL682968 | 0.90 | GFER (0.49) | GFERRAB9AALKCCR1CTSB | |
| SCHEMBL682979 | 0.82 | PDE4B (0.53) | GFERRAB9ACTSBCTSSCTSK | |
| SCHEMBL2142877 | 0.77 | NR1H2 (0.43) | ALKCCR1KMT2AMEN1 | |
| SCHEMBL873991 | 0.77 | NR1H2 (0.43) | ALKCCR1KMT2AMEN1 | |
| SCHEMBL682544 | 0.75 | PDE4D (0.48) | RAB9AALKCTSBCTSSCTSK | |
| SCHEMBL3771993 | 0.74 | LMNA (0.54) | GFERCCR1KMT2ALMNAGAA | |
| SCHEMBL873466 | 0.73 | ADRB1 (0.51) | ALK | |
| SCHEMBL681899 | 0.73 | PDE4B (0.53) | GFERRAB9ACTSBCTSSCTSK | |
| SCHEMBL2139373 | 0.73 | HIF1A (0.41) | ALKCCR1CTSBCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927546-B2 | Therapeutic piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2015-01-06 | — | — | US | disclosed |
| US-20110065691-A1 | THERAPEUTIC PIPERAZINES | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065691-A1 | THERAPEUTIC PIPERAZINES | PDE4A, PDE4B, PDE4D | GFER 3906/4885RAB9A 1524/4885ALK 3664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.